ADEL K EL-NAGGAR to Antineoplastic Agents
This is a "connection" page, showing publications ADEL K EL-NAGGAR has written about Antineoplastic Agents.
Connection Strength
0.505
-
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012 Jan; 16(1):103-19.
Score: 0.081
-
Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment With Ipilimumab and Radiation Therapy. J Immunother. 2018 09; 41(7):336-339.
Score: 0.032
-
Met Receptor Tyrosine Kinase and Chemoprevention of Oral Cancer. J Natl Cancer Inst. 2018 03 01; 110(3).
Score: 0.031
-
The KRAS-Variant and Cetuximab Response in Head and Neck Squamous Cell Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2017 Apr 01; 3(4):483-491.
Score: 0.029
-
Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. J Clin Oncol. 2017 Jan 20; 35(3):352-360.
Score: 0.028
-
Phase II study of gefitinib in patients with advanced salivary gland cancers. Head Neck. 2015 May; 37(5):644-9.
Score: 0.025
-
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res. 2015 Apr 01; 75(7):1205-15.
Score: 0.025
-
The role of trastuzumab in the management of salivary ductal carcinomas. Anticancer Res. 2013 Jun; 33(6):2587-91.
Score: 0.022
-
Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo. Head Neck. 2013 Mar; 35(3):321-8.
Score: 0.020
-
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 Mar 01; 18(5):1435-46.
Score: 0.020
-
Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer. 2011 May 15; 117(10):2112-9.
Score: 0.019
-
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila). 2009 Jan; 2(1):14-21.
Score: 0.016
-
Vandetanib inhibits growth of adenoid cystic carcinoma in an orthotopic nude mouse model. Clin Cancer Res. 2008 Aug 15; 14(16):5081-9.
Score: 0.016
-
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther. 2008 May; 7(5):1001-6.
Score: 0.016
-
Concomitant inhibition of epidermal growth factor and vascular endothelial growth factor receptor tyrosine kinases reduces growth and metastasis of human salivary adenoid cystic carcinoma in an orthotopic nude mouse model. Mol Cancer Ther. 2006 Nov; 5(11):2696-705.
Score: 0.014
-
Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma. Clin Cancer Res. 2006 Aug 01; 12(15):4755-65.
Score: 0.014
-
Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer. Mol Cancer Ther. 2005 Aug; 4(8):1146-56.
Score: 0.013
-
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 2004 Dec 15; 10(24):8594-602.
Score: 0.012
-
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells. Clin Cancer Res. 2004 Jan 15; 10(2):658-67.
Score: 0.012
-
Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001 Oct; 7(10):2984-97.
Score: 0.010
-
Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 1999 Oct; 125(10):1083-9.
Score: 0.009
-
Telomerase activity in cancer: a magic bullet or a mirage? Adv Anat Pathol. 1998 Mar; 5(2):86-94.
Score: 0.008
-
Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522. Int J Radiat Oncol Biol Phys. 2017 03 15; 97(4):687-699.
Score: 0.007
-
Risk Factors and Prognosis for Myoepithelial Carcinoma of the Major Salivary Glands. Ann Surg Oncol. 2015 Oct; 22(11):3701-7.
Score: 0.006
-
KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma. Oncogene. 2011 Jul 14; 30(28):3163-73.
Score: 0.005
-
Intensity-modulated radiotherapy for cervical node squamous cell carcinoma metastases from unknown head-and-neck primary site: M. D. Anderson Cancer Center outcomes and patterns of failure. Int J Radiat Oncol Biol Phys. 2010 Nov 15; 78(4):1005-10.
Score: 0.004
-
Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res. 2007 Jul 15; 13(14):4291-9.
Score: 0.004
-
Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate. Histol Histopathol. 2004 04; 19(2):565-74.
Score: 0.003
-
Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Ther. 2000 Mar; 7(3):422-9.
Score: 0.002
-
Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst. 1998 Oct 21; 90(20):1545-51.
Score: 0.002